Literature DB >> 16225752

CPU 86017, p-chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway.

Tian-tai Zhang1, Bing Cui, De-zai Dai, Wei Su.   

Abstract

AIM: To elucidate the involvement of the endothelin (ET) pathway in the pathogenesis of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and the therapeutic effect of CPU 86017 (p-chlorobenzyltetrahydroberberine chloride) in rats.
METHODS: Rats were injected with a single dose (60 mg/kg, sc) of MCT and given CPU 86017 (20, 40, and 80 mg/kg-1/d-1, po) or saline for 28 d. The hemodynamics, mRNA expression, and vascular activity were evaluated.
RESULTS: Right ventricular systolic pressure and central venous pressures were elevated markedly in the PAH model and decreased by CPU 86017. In the PAH group, the endothelin-1 (ET-1) in serum and lungs was dramatically increased by 54% (79.9 pg/mL, P<0.01) and 93% (166.2 pg/mL, P<0.01), and mRNA levels of preproET-1, eNOS, and iNOS also increased dramatically compared with control. Compared with PAH group, CPU 86017 decreased the content of ET-1 to the normal level in lung tissue, but was less effective in serum. The level of NO was significantly increased in CPU 86017 at 80 and 40 mg/kg-1/d-1 groups in tissue, whereas the difference in serum was not significant. A significant reduction in MDA production and an increase in the SOD activity in the serum and lungs was observed in all three CPU 86017 groups. CPU 86017 80 mg/kg-1/d-1 po increased the activity of cNOS by 33% (P<0.01). The up-regulation of eNOS and iNOS mRNA levels induced by MCT was significantly reversed in 3 CPU 86017 groups, and preproET-1 mRNA abundance was also reduced notably in CPU 86017 80 mg/kg-1/d-1 group vs the PAH group. The KCl-induced vasoconstrictions in the calcium-free medium decreased markedly in PAH group but recovered partially after CPU 86017 intervention. The constrictions in the presence of Ca(2+) was not improved by CPU 86017. The phenylephrine-induced vasoconstrictions in the calcium-free medium decreased markedly in PAH group but not recovered after CPU 86017 intervention. The constrictions in the presence of Ca(2+) completely returned to the normal after CPU 86017 intervention.
CONCLUSION: CPU 86017 suppressed MCT-induced PAH mainly through an indirect suppression of the ET-1 system, which was involved in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225752     DOI: 10.1111/j.1745-7254.2005.00214.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  11 in total

1.  CPU86017-RS attenuate hypoxia-induced testicular dysfunction in mice by normalizing androgen biosynthesis genes and pro-inflammatory cytokines.

Authors:  Guo-lin Zhang; Feng Yu; De-zai Dai; Yu-si Cheng; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

2.  Raisanberine protected pulmonary arterial rings and cardiac myocytes of rats against hypoxia injury by suppressing NADPH oxidase and calcium influx.

Authors:  Jie Gao; Yi-qun Tang; De-zai Dai; Yu-si Cheng; Guo-lin Zhang; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

3.  Activation of GPER ameliorates experimental pulmonary hypertension in male rats.

Authors:  Allan K Alencar; Guilherme C Montes; Tadeu Montagnoli; Ananssa M Silva; Sabrina T Martinez; Aline G Fraga; Hao Wang; Leanne Groban; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Eur J Pharm Sci       Date:  2016-11-09       Impact factor: 4.384

4.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

5.  CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity.

Authors:  Min-you Qi; Yu Feng; De-zai Dai; Na Li; Yu-si Cheng; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

6.  Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats.

Authors:  Allan K N Alencar; Sharlene L Pereira; Tadeu L Montagnoli; Rodolfo C Maia; Arthur E Kümmerle; Sharon S Landgraf; Celso Caruso-Neves; Emanuelle B Ferraz; Roberta Tesch; José H M Nascimento; Carlos M R de Sant'Anna; Carlos A M Fraga; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

7.  CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation.

Authors:  Na Li; De-Zai Dai; Yin Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

Review 8.  Role of endothelin receptor A and NADPH oxidase in vascular abnormalities.

Authors:  De-Zai Dai; Yin Dai
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

Review 9.  Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.

Authors:  Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T S Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Ziberna; Mohamad Fawzi Mahomoodally; Gokhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

Review 10.  Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.

Authors:  José L Sánchez-Gloria; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Roxana Carbó; Adrián Hernández-Díazcouder; Carlos A Guzmán-Martín; Ivan Rubio-Gayosso; Fausto Sánchez-Muñoz
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.